<div id="readability-page-1"><div><p>Ono Pharmaceutical (TSE:4528) closed out FY 2026 with fourth quarter revenue of ¥118.7 billion and basic EPS of ¥1.74, set against trailing twelve month revenue of ¥515.8 billion and EPS of ¥148.49 that came with 39.4% earnings growth and a 13.5% net margin versus 10.3% a year earlier. Over the past few quarters, revenue has ranged from ¥127.5 billion to ¥139.9 billion with quarterly EPS moving between ¥37.62 and ¥61.42. This frames the latest print within a year of higher profitability and a steadily built earnings base.</p> <p>See our full analysis for Ono Pharmaceutical.</p><p>With the headline numbers on the table, the next step is to set these results against the most common narratives around Ono Pharmaceutical to see which storylines still hold up and which ones the new margins begin to challenge.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/659028ff-e6bd-446d-8a5e-51a934043f4d/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/659028ff-e6bd-446d-8a5e-51a934043f4d/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA5"/><figcaption>TSE:4528 Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>39.4% earnings growth, but forecasts point to a 5.7% annual decline</h2> <ul> <li>Trailing twelve month earnings grew 39.4% with net income at ¥69,767 million and net margin at 13.5% versus 10.3% a year earlier. Analysts expect earnings to decline by about 5.7% per year and revenue by about 4% per year over the next three years.</li> <li>What stands out for a bearish narrative that focuses on future contraction is the tension between the recent profitability and the forward view:     <ul> <li>On one hand, the last year shows stronger profitability, with trailing EPS rising to ¥148.49 and net margin at 13.5%, which challenges a simple story that the business is already weakening.</li> <li>On the other hand, forecasts for earnings and revenue to decline over several years line up with a cautious stance that recent strength may not persist, so bears can still point to that projected multi year downtrend as their key concern.</li> </ul> </li> </ul><p> Stay level headed by testing how this cautious outlook compares with a detailed bear case for Ono Pharmaceutical.<strong>🐻 Ono Pharmaceutical Bear Case</strong></p><h2>TTM revenue steady around ¥515.8b while quarterly profit swings</h2> <ul> <li>On a trailing basis, revenue sits at ¥515,785 million with net income of ¥69,767 million. Within FY 2026, quarterly revenue moved between ¥118,749 million and ¥139,900 million and quarterly net income ranged from a loss of ¥6,545 million in FY 2025 Q4 to ¥28,860 million in FY 2026 Q3.</li> <li>What is interesting for a bullish angle that highlights resilience is how the full year picture differs from the quarter to quarter noise:     <ul> <li>Bulls can point to the shift from a FY 2025 Q4 loss of ¥6,545 million to positive net income in all four FY 2026 quarters, including ¥28,860 million in Q3, as evidence that the business can absorb setbacks and still deliver profitable trailing results.</li> <li>At the same time, the wide spread between Q4 FY 2025 and Q3 FY 2026 profit reminds readers that the earnings path can be bumpy even when the trailing totals look solid, so bullish arguments need to account for this volatility rather than assuming a smooth path.</li> </ul> </li> </ul> <h2>P/E of 16.7x, 3.23% yield and price below DCF fair value</h2> <ul> <li>The stock trades on a trailing P/E of 16.7x compared with peers at 17.8x and the JP Pharmaceuticals average at 15.4x. It offers a 3.23% dividend yield and sits below a DCF fair value of ¥3,234.32 at a current share price of ¥2,480.50, which is about 23.3% under that DCF figure.</li> <li>Bullish arguments that the stock offers reasonable value with income are strongly shaped by this mix of metrics:     <ul> <li>Supporters can highlight that the P/E is lower than peers while still backed by a 13.5% trailing net margin and 39.4% earnings growth over the past year, which they may see as a constructive set up.</li> <li>At the same time, the 3.23% dividend yield and gap to DCF fair value sit alongside forecasts for earnings and revenue to decline, so any bullish view has to weigh the income and valuation signals against those projected multi year declines.</li> </ul> </li> </ul><p> If you want to see how these valuation signals fit into a fuller long term story, check out what other investors are saying about Ono Pharmaceutical.<strong>📊 Read the what the Community is saying about Ono Pharmaceutical.</strong></p><h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Ono Pharmaceutical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>Given the mix of cautious forecasts and solid trailing profitability, this is a moment to move quickly, review the detailed numbers yourself, and decide where you stand on Ono Pharmaceutical's risk and reward balance. You can then pressure test that view against our breakdown of the 3 key rewards and 1 important warning sign.</p> <h2>Explore Alternatives</h2> <p>Ono Pharmaceutical combines recent profitability with forecasts for multi year earnings and revenue decline, as well as visible quarterly volatility that may not suit every investor.</p> <p>If those uncertainties leave you wanting steadier prospects, use the 53 resilient stocks with low risk scores to quickly spot companies with more resilient profiles and potentially smoother earnings paths.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

4528

<p>Ono Pharmaceutical (TSE:4528) reported FY 2026 Q4 revenue of ¥118.7 billion and EPS of ¥1.74, achieving 39.4% earnings growth and a net margin of 13.5%. Despite strong past performance, analysts forecast a 5.7% annual decline in earnings and a 4% drop in revenue over the next three years. The stock trades at a P/E of 16.7x, below peers, with a 3.23% dividend yield, but concerns about future profitability persist. Investors are advised to consider long-term trends and valuations before making decisions.</p>

Ono Pharmaceutical (TSE:4528) Earnings Growth Versus Forecast Declines Tests Bull And Bear Narratives